Today's Rundown Mirati sets date for closely watched clinical KRAS readout UCB's bispecific beats J&J's Stelara in psoriasis phase 3 Gilead, Spring Bank’s Hep B combo shows ‘incremental benefit,’ but all eyes on higher doses: analysts [Sponsored] A New Starting Point for Patient Support: Technology-Driven Hub Services Blocking tumor evolution to halt cancer drug resistance EuroBiotech Report—Healx and Abalos raise cash, Ipsen bags Blueprint drug, Gilead and ReNeuron FiercePharmaAsia—Daiichi, AZ's FDA priority review; Torrent's 'sartan' mess; Takeda-Acino deal Chutes & Ladders—Gilead Sciences names Dickinson to CFO role Featured Story | | | Friday, October 18, 2019 Mirati Therapeutics is set to reveal the first clinical data on its closely watched KRAS G12C inhibitor MRTX849 Oct. 28. The readout is a key moment in the fairly short history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset. |
|
|---|
|
Top Stories Friday, October 18, 2019 UCB’s bimekizumab has beaten Johnson & Johnson’s Stelara in a phase 3 psoriasis trial. The bispecific inhibitor of IL-17A and IL-17F outperformed J&J’s blockbuster incumbent against an endpoint that tracked the proportion of patients achieving a 90% reduction in psoriasis symptoms. Friday, October 18, 2019 Spring Bank Pharmaceuticals’ hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in more than one-fifth of patients in a phase 2 study—a result that Jefferies analysts called an “incremental positive benefit” over either drug alone. The data set the stage for potentially better performances from higher doses. Monday, October 14, 2019 Flipping the script for specialty medications – improved patient access and time-to-therapy with a new tech-enabled platform from CoverMyMeds and RxCrossroads by McKesson. Thursday, October 17, 2019 Researchers are developing a new class of drug to block the tumor DNA mutations that allow certain cancer cells to avoid the body’s immune responses and treatments, which can lead to the proliferation of hard-to-kill, drug-resistant strains. Thursday, October 17, 2019 In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug. Friday, October 18, 2019 AstraZeneca and Daiichi Sankyo's breast cancer antibody-drug conjugate gets an FDA priority review. FDA publicly slams Torrent Pharma as a main culprit in the global recall of tainted "sartan" drugs. Takeda sells some 30 emerging markets drugs to Swiss firm Acino International. And more. Friday, October 18, 2019 Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO. | | Experts in our field; with 20+ years of experience in Viral Vector and plasmid DNA (R&D, High Quality and GMP) manufacture for pre-clinical, clinical and commercial supply. Take a virtual tour of our facilities and find out more about our most recent expansion project. |
Resources Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Medidata Simplified filing, improved oversight, audit readiness: is your eTMF system delivering best-in-class benefits? Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Cortellis, a Clarivate Analytics Solution Download this report for full details of Life sciences M&As in the second quarter of 2019 with notes and trends. Sponsored by: Elligo Health Research Find out how it leverages real-world data and novel IntElligo Research Stack™ technology to help researchers battle rising costs, cumbersome processes, and stagnant participation — bridging the gap between research and care. Sponsored by: InformedDNA Download this complimentary guide paper that explores key strategies for a successful genetics-informed clinical trial. Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BioAnalytix, Inc. Download the White Paper and learn how detailed characterization can guide successful development of gene therapy products. Sponsored by: ON24 Compare digital program performance and audience engagement among your life sciences peers. Sponsored by: Decision Resources Group Clinically Integrated Networks are vehicles for powerful IDNs to extend their influence into the physician sector and play a key role for IDNs trying to pave a path to becoming a self-contained healthcare ecosystem. Sponsored by: Reprints Desk, Inc. Slashing your R&D costs is easier than you think. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Blue Matter, strategic consultants in the life sciences White paper providing an overview of precision medicine in oncology, as well as a look ahead at future developments and keys to success for pharmaceutical and diagnostics companies. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. BioBasics: Biotech For The Non-Scientist Oct 22-23, 2019 | San Diego, CA 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Immersion November 7-8, 2019 | Boston, MA Advanced Therapies: Immunotherapies, Cell Therapies and Gene Therapies November 15, 2019 | Boston, MA Countdown to Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register Now at www.drugstomarket.com/drugbootcamp and start Pre-Boot Camp Preparation | 